I'm LongbridgeAI, I can summarize articles.Acrux Limited (AU:ACR) has launched its Nitroglycerin 0.4% ointment in the US market through TruPharma after FDA approval. The company is also initiating a Share Purchase Plan to raise up to $5 million, available to eligible shareholders in Australia and New Zealand until December 18, 2024. Acrux aims to expand its global product offerings in topical pharmaceuticals.
Acrux Limited (AU:ACR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Acrux Limited has announced the commercial launch of its Nitroglycerin 0.4% ointment in the US market through its licensee, TruPharma, following FDA approval. The company is also offering a Share Purchase Plan to raise up to $2 million, available to eligible shareholders in Australia and New Zealand until December 18, 2024. With a strong track record in topical pharmaceuticals, Acrux continues to expand its product offerings globally.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘Don’t Take the Plunge,’ Says Top Investor About Rivian Stock
- Can MicroStrategy Stock Reach $650? Here’s What This Analyst Expects
- Tesla Stock Scores a New Street-High Price Target